Weight loss injections and hair health

The study focused on the relationship between the use of weight loss medications from the "GLP-1" class, such as Mounjaro and Wegovy, and an increased risk of hair loss. Hair loss cases were observed approximately one year after starting treatment, with the incidence rate reaching about 70% compared to users of other diabetes medications such as DPP-4 inhibitors. The potential cause is attributed to nutritional deficiencies resulting from reduced calorie intake, with hormonal and metabolic effects of the drugs possibly being another factor. Although hair loss does not cause physical harm, it can have psychological and social impacts. The U.S. Food and Drug Administration is currently evaluating these potential safety signals.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل